ARTICLE | Clinical News
Trabedersen regulatory update
July 30, 2012 7:00 AM UTC
FDA granted Orphan Drug designation for Antisense's trabedersen to treat malignant melanoma. The transforming growth factor (TGF) beta 2 antisense oligonucleotide is in Phase I/II testing in patients...